These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38727236)

  • 21. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
    Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM
    J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
    Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
    Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
    Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
    Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.
    Boumelha J; de Castro A; Bah N; Cha H; de Carné Trécesson S; Rana S; Tomaschko M; Anastasiou P; Mugarza E; Moore C; Goldstone R; East P; Litchfield K; Lee SH; Molina-Arcas M; Downward J
    Cancer Res; 2024 Jul; 84(14):2231-2246. PubMed ID: 38635884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
    Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
    Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The KRAS
    Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
    Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
    Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
    Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers.
    Li B; Feng Y; Hou Q; Fu Y; Luo Y
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
    Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
    Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive Microenvironment.
    Benslimane Y; Amalfi K; Lapin S; Perrino S; Brodt P
    Cancer Res Commun; 2024 Aug; 4(8):1963-1977. PubMed ID: 39007345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
    Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
    Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
    Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.
    Mehra S; Garrido VT; Dosch AR; Lamichhane P; Srinivasan S; Singh SP; Zhou Z; De Castro Silva I; Joshi C; Ban Y; Datta J; Gilboa E; Merchant NB; Nagathihalli NS
    Cancer Res Commun; 2023 Jul; 3(7):1224-1236. PubMed ID: 37448553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.
    Chibaya L; DeMarco KD; Lusi CF; Kane GI; Brassil ML; Parikh CN; Murphy KC; Chowdhury SR; Li J; Ma B; Naylor TE; Cerrutti J; Mori H; Diaz-Infante M; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    Sci Transl Med; 2024 Aug; 16(762):eadj9366. PubMed ID: 39196958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.